目的 研究分析视网膜激光光凝治疗糖尿病视网膜病变的临床疗效.方法 选取我院2017年6月至2018年6月收治的200例糖尿病视网膜病变患者作为研究对象,所有患者均给予视网膜激光光凝术进行治疗,观察其临床治疗效果.结果 所有患者经治疗后的视力恢复情况:视力降低者11(5.5％)例,临床治疗总有效率为94.5％.所有患者均未出现视网膜脱落等情况;且未发生视网膜出血、眼压升高及晶状体混浊等并发症.结论 做好针对该疾病的早期治疗对降低致盲率,促进患者健康恢复有着积极作用.当前在临床中主要有药物治疗、激光光凝治疗、冷凝治疗等方式,激光光凝治疗作为治疗该病症最好的方式,对糖尿病视网膜病变患者行视网膜激光光凝术治疗,能有效改善患者视力水平,其临床治疗效果显著,值得在临床中推广并应用.
目的 观察重组人血管内皮抑制素(恩度)联合化疗药物治疗恶性胸腔积液的疗效.方法 选取乳腺癌所致恶性胸腔积液患者90例,根据其不同的治疗方式将其分为观察组以及对照组,每组45例.观察组应用恩度联合化疗药物治疗,对照组单独应用化疗药物治疗,治疗前均先排尽胸腔积液.治疗组在胸腹腔内注入顺铂60 mg、恩度45～60 mg;对照组除不加入恩度外,其余同治疗组.比较2组治疗效果.结果 观察组的总有效率为77.78％(35/45),对照组为44.44％,组间差异有统计学意义(x2=5.372,P＜0.05).观察组生活质量改善率为55.26％;对照组为33.33％,组间差异有统计学意义(x2 =4.500,P＜0.05).2组的不良反应发生率分别达到了35.56％和33.33％,差异无统计学意义(P＞0.05).治疗前,2组红细胞数无统计学差异(P＞0.05);治疗后,观察组较对照组红细胞数显著减少(P＜0.05).结论 对于乳腺癌所致的恶性胸腔积液采用胸腔内灌注顺铂序贯恩度治疗安全、有效,值得临床推广应用.
目的:观察改良翼状胬肉手术的临床疗效.方法:对翼状胬肉患者21 2例,行翼状胬肉切除转移术,复发胬肉加0.02％丝裂霉素术后观察3个月1.5年.结果:治疗组1 06例中没有一例复发,角膜光滑,术后散光小,外观好,无并发症,治愈率100％;对照组:106例,复发1 6例,角膜不光滑,术后散光大,治愈率达85％,两者比较差异有统计学意义(P＜0.05).结论:改良翼状胬肉手术治疗效果肯定.
Objective To investigate the relationship between intraocular pressure(IOP) and ocular axial length and retinal vein occlusion(RVO).Methods The IOP of affected and fellow eyes of 56 patients with RVO were measured with Canon TX-F Full Auto Tonometer.The axial lengths of affected and fellow eyes with RVO were performed with A-scan ultra sonography.The control group consisted of age-and sex-matched 98 patients with cataract.Results The affected eyes with CRVO had a significant lower IOP compared with the fellow and control eyes(P<0.01).The affected eyes with BRVO had not significant difference compared with the fellow and control eyes(P>0.05).The difference in axial length between the eyes with CRVO and the eyes in the control group was statistically significant(P<0.01).The difference in axial length between the eyes with BRVO and the control eyes was not statistically significant(P>0.05).Conclusion Short axial length is one of the risk factor for CRVO and there was a reduction of IOP in eyes associated with CRVO.The short axial length is not a risk factor to BRVO and there was not a reduction of IOP in eyes with BRVO.
